Keyword Connections

•  Anna Means
•  Guoqiang Gu
•  Haibo Jia

•  Kathy DelGiorno
•  Leah Potter
•  Leon Raskin

•  Lucia Rameh Plant
•  Michael VanSaun
•  Nagaraj Nagathihalli

Resources

• Featured Investigator : Magnuson, Dr. Mark
• Featured Publication

Communities

• Gu Lab
• Islet Procurement and Analysis Core

Publications

• Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
  Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T
  (2019) Nature 569: 131-135
• Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.
  McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, Carrer A, Salz TH, Natsume S, Stauffer KM, Makohon-Moore A, Zhong Y, Wu H, Wellen KE, Locasale JW, Iacobuzio-Donahue CA, Feinberg AP
  (2017) Nat Genet 49: 367-376
• A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.
  Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF, Hoover RN, Hartge P, Chanock SJ
  (2010) Nat Genet 42: 224-8
• RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.
  Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR
  (2015) Cell 161: 1345-60
• Cysteine depletion induces pancreatic tumor ferroptosis in mice.
  Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, Decker AR, Sastra SA, Palermo CF, Andrade LR, Sajjakulnukit P, Zhang L, Tolstyka ZP, Hirschhorn T, Lamb C, Liu T, Gu W, Seeley ES, Stone E, Georgiou G, Manor U, Iuga A, Wahl GM, Stockwell BR, Lyssiotis CA, Olive KP
  (2020) Science 368: 85-89
• Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.
  Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP, Pan FC, Akiyama H, Wright CV, Jensen K, Hebrok M, Sander M
  (2012) Cancer Cell 22: 737-50
• Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
  Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, Cancer Genome Atlas Research Network
  (2017) Cancer Cell 32: 185-203.e13
• EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
  Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT
  (2012) Cancer Cell 22: 304-17
• Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
  Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA
  (2003) Cancer Cell 4: 437-50
• Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
  Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R
  (2014) Cancer Cell 25: 719-34
• Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
  DelGiorno KE, Carlson MA, Osgood R, Provenzano PP, Brockenbough JS, Thompson CB, Shepard HM, Frost GI, Potter JD, Hingorani SR
  (2014) Cancer Cell 26: 16-7
• Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.
  Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM
  (2016) Nat Med 22: 497-505
• Regulation of net hepatic glucose uptake in vivo.
  Pagliassotti MJ, Cherrington AD
  (1992) Annu Rev Physiol 54: 847-60
• Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
  Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J
  (2009) J Clin Oncol 27: 5660-9
• Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
  Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB
  (2009) J Clin Oncol 27: 3778-85
• Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
  Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ
  (2008) J Clin Oncol 26: 942-7
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
  Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB
  (2002) J Clin Oncol 20: 3270-5
• Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children.
  Chan E, Berlin J
  (2014) J Clin Oncol 32: 487-8
• Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
  Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB
  (2000) J Clin Oncol 18: 3384-9
• Past and future of pancreas cancer: are we ready to move forward together?
  Merchant N, Berlin J
  (2008) J Clin Oncol 26: 3478-80
• Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.
  Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang R, Sansom OJ, Adams PD
  (2011) Mol Cell 42: 36-49
• Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop.
  Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB, National Heart, Lung and Blood Institute/Office of Rare Diseases
  (2004) Circulation 109: 2947-52
• Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.
  Berlin J, Benson AB
  (2010) Nat Rev Clin Oncol 7: 135-7
• Pancreas-specific Cre driver lines and considerations for their prudent use.
  Magnuson MA, Osipovich AB
  (2013) Cell Metab 18: 9-20
• Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells.
  Abbott DW, Freeman ML, Holt JT
  (1998) J Natl Cancer Inst 90: 978-85
• Pancreas cancer on the rise: are we up to the challenge?
  Cardin DB, Berlin JD
  (2013) J Natl Cancer Inst 105: 1675-6
• p120ctn-Mediated Organ Patterning Precedes and Determines Pancreatic Progenitor Fate.
  Nyeng P, Heilmann S, Löf-Öhlin ZM, Pettersson NF, Hermann FM, Reynolds AB, Semb H
  (2019) Dev Cell 49: 31-47.e9